Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well taselisib (GDC-0032) works in treating patients with
stage IV squamous cell lung cancer that has come back after previous treatment. This is a
sub-study that includes all screened patients positive for the phosphoinositide 3-kinase
(PI3K) biomarker. PI3K can cause tumor cells to grow more quickly. Taselisib may decrease the
activity of PI3K and may be able to shrink tumors.